Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2026-05-20 Regulatory Filings
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 54% confidence The document is a corporate press release announcing product regulatory approvals and first commercial sales in new markets. It does not contain earnings data, detailed financial statements, a shareholder meeting notice, or any of the specialized filings (e.g., 10-K, IR, ER, DIRS, DIV, PSI, etc.). It is a general corporate announcement of regulatory developments and commercial expansion, which best fits the fallback category for miscellaneous regulatory and corporate announcements, i.e., Regulatory Filings (RNS).
2026-05-20 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a corporate press release (“COMMUNIQUÉ DE PRESSE”) announcing regulatory approvals in the UAE and Turkey and the first commercial sales of a medical device (CellTolerance). It does not present financial results, an earnings release, a shareholder meeting notice, or detailed management discussion. It is a general corporate/regulatory announcement that does not fit into a more specific category, making “Regulatory Filings (RNS)” the appropriate fallback.
2026-05-20 French
Informations privilégiées / Autres communiqués
Regulatory Filings
2026-05-18 French
Inside Information / Other news releases
Regulatory Filings
2026-05-18 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Major Shareholding Notification Classification · 95% confidence The document is a press release providing monthly information about the total number of voting rights and shares comprising the share capital of Mauna Kea Technologies. It references specific articles of the Commercial Code and AMF regulations related to voting rights disclosure. The content is a regulatory announcement about share capital and voting rights, not a full report or detailed financial statement. The document length is short (2009 characters), and it does not contain financial data or detailed analysis. Therefore, it fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or status in share ownership and voting rights.
2026-05-04 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Major Shareholding Notification Classification · 95% confidence The document is a press release from Mauna Kea Technologies providing information about the total number of voting rights and shares composing the share capital as of a specific date. It references French commercial code articles and AMF regulations, indicating a regulatory disclosure related to share capital and voting rights. The document is short (2191 characters) and does not contain financial statements, management discussion, or detailed report content. It is not announcing a meeting, voting results, or management changes, but rather providing an update on share capital and voting rights. This fits the category of Major Shareholding Notification or similar, but since it is about total voting rights and share capital composition rather than changes in significant share ownership thresholds, it aligns best with the category for notifications about share capital and voting rights. Given the definitions, the closest match is Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related disclosures about shareholding structure. Confidence is high because the document clearly focuses on voting rights and share capital information as per regulatory requirements.
2026-05-04 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.